Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for System Suitability Test Before Bioanalysis – V 2.0

Posted on By

BA-BE Studies: SOP for System Suitability Test Before Bioanalysis – V 2.0

Standard Operating Procedure for System Suitability Test (SST) Before Bioanalysis in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/162/2025
Supersedes SOP/BA-BE/162/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for performing System Suitability Tests (SST) prior to initiating sample analysis on LC-MS/MS systems to ensure that the bioanalytical method is performing acceptably for BA/BE studies.

2. Scope

This SOP is applicable to all analysts and scientific staff involved in operating LC-MS/MS instrumentation for quantitative bioanalysis of plasma samples in BA/BE studies.

3.

Responsibilities
  • Analyst: Performs SST and evaluates results based on predefined acceptance criteria.
  • QA Reviewer: Reviews SST data and logs prior to bioanalytical batch release.
  • Lab Supervisor: Approves continuation of analysis based on successful SST performance.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring that SSTs are executed as per validated protocols and documented before bioanalytical sample analysis begins.

5. Procedure

5.1 Pre-Requisites

  1. Ensure LC-MS/MS instrument setup and calibration is complete as per SOP/BA-BE/161/2025.
  2. Verify that mobile phases and column are equilibrated.
  3. Prepare and label system suitability solutions (SSS) per validated method SOP.

5.2 Injection and Evaluation

  1. Inject the SSS at the beginning of the sequence using the same injection parameters defined in the bioanalytical method.
  2. Evaluate the following system performance criteria:
    • Retention time (RT) within ±2% of validated value.
    • Signal-to-noise (S/N) ratio ≥ 10 at LLOQ.
    • Peak shape: Symmetry factor between 0.8 to 1.5.
    • Resolution between analyte and IS > 2 (if applicable).
    • Area reproducibility: RSD for 5 replicate injections < 5%.

5.3 System Suitability Logs

  1. Record all SST parameters in Annexure-1: SST Summary Log.
  2. Include chromatograms, peak integration results, and calculations.

5.4 Deviation Handling

  1. If any parameter fails the acceptance criteria:
    • Do not proceed with sample analysis.
    • Investigate cause: mobile phase composition, column issues, or instrument error.
    • Repeat SST after corrective action.
    • Document deviations in Annexure-2: SST Deviation Log.

5.5 Re-Qualification

  1. If three consecutive SST failures occur:
    • Requalify LC-MS/MS system.
    • Notify QA and pause all active sequences.

5.6 Approval to Proceed

  1. Only after SST pass results are reviewed and signed by the Lab Supervisor and QA personnel may the analyst initiate injection of study samples.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • SST: System Suitability Test
  • SSS: System Suitability Solution
  • RSD: Relative Standard Deviation
  • RT: Retention Time
  • IS: Internal Standard

7. Documents

  1. SST Summary Log – Annexure-1
  2. SST Deviation Log – Annexure-2

8. References

  • ICH M10: Bioanalytical Method Validation
  • FDA and EMA Bioanalytical Method Guidance
  • Internal Bioanalytical Method SOPs

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: SST Summary Log

Date Instrument ID Analyte RT Peak Area S/N Ratio RSD (%) Result
17/04/2025 LCMS-004 Metoprolol 2.35 83546 28 2.1 Pass

Annexure-2: SST Deviation Log

Date Run ID Parameter Failed Cause Corrective Action Reviewed By
17/04/2025 SST-BE-22 RT Shift Column Pressure Fluctuation Column Flushed Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Added S/N criteria and RSD thresholds Regulatory Review QA Head
See also  BA-BE Studies: SOP for Trial Registration with EudraCT - V 2.0
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Labeling of Dispensed Materials – V 2.0
Next Post: Gel Manufacturing: SOP for Operating Sealing Machines for Gel Tubes – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version